Pharmaceutical Research Unit, Jordan

The Pharmaceutical Research Unit (PRU) is the first contract research organization established in Jordan (1993), headquartered in Amman and accredited by the US FDA, EU authorities, and multiple MENA health agencies. PRU served as the clinical site and collaborating organization for Lobe Sciences' Phase 1 first-in-man pharmacokinetic study of psilocin mucate (L-130), a stabilized psilocin salt with near-100% bioavailability investigated as a low-dose at-home therapeutic.